On February 19, 2026, CRISPR Therapeutics reported groundbreaking interim data from its ongoing Phase 1b clinical trial of CTX310, an investigational in vivo base editing therapy. The single intravenous infusion
On February 2, 2026, SpaceX announced the acquisition of xAI, Elon Musk’s artificial intelligence venture, in the largest merger and acquisition transaction in history. The all-stock deal values xAI
